HeartBeam, Inc. (NASDAQ:BEAT) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder & Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. At this time, I'll turn the call ove ...

公司业务及产品 - 公司是一家专注于开发和商业化高分辨率的可穿戴心电图（ECG）解决方案的医疗技术公司[53] - 公司通过专有和获得专利的矢量心电图（VECG）技术平台实现了开发高分辨率ECG解决方案的能力[54] - 公司正在开发远程监测高危冠状动脉疾病患者的HeartBeam AIMIGo产品，该产品的缺血检测系统可能比现有的远程心脏健康监测解决方案更准确[56] - 公司已为HeartBeam AIMIGo开发了一个可行的原型，并最近为该设备提交了510(k)申请[57] - 公司撤回了针对急诊室使用的HeartBeam AIMI™产品的FDA 510(k)申请，以便专注于HeartBeam AIMIGo产品的发展[58] - 公司的产品和服务被FDA分类为II类医疗器械，需要通过510(k)预市场通知流程或De-Novo流程获得FDA的批准[59] 知识产权 - 公司拥有十项已发行的美国专利和八项待定的美国申请，以及在其他国家的专利[60] 公司发展及财务 - 公司在2023年6月底拥有10名员工，计划根据增长战略雇佣或聘请更多专业人员[61] - 公司在2023年5月完成了一笔约2500万美元的二次发行，以及一笔100万美元的直接注册发行[62] - 公司在2023年6月提交了HeartBeam AIMIGo设备的510(k)申请，并撤回了针对HeartBeam AIMI™产品的FDA 510(k)申请[64] - 2022年6月30日结束的六个月内，融资活动提供的净现金为300万美元，主要来源于根据2月股票购买协议发行普通股[83] 财务报表 - 公司没有持有任何衍生工具，也不进行任何套期保值活动[84] - 公司的管理人员认为未经审计的财务报表和本季度报告中包含的其他财务信息在所有重要方面公平地呈现了公司的财务状况、经营业绩和现金流量[87]

HeartBeam, Inc. (NASDAQ:BEAT) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Rob Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam First Quarter 2023 Financial Results Conference Call. At this time all participants are in listen ...

Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41060 HEARTBEAM, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4881450 ...

Medical Grade Heart Attack Detection Always with the patient mbe88 Fourth Quarter and Full Year 2022 Financial Results Conference Call NASDAQ: BEAT March 16, 2023 Fourth Quarter 2022 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strate ...

HeartBeam, Inc. (NASDAQ:BEAT) Q4 2022 Results Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings. And welcome to the HeartBeam Fourth Quarter and Full-Year 2022 Financial Results Conference Call. At this time, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41060 HEARTBEAM, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4881450 State or Other Jurisdi ...

HeartBeam, Inc. (NASDAQ:BEAT) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Branislav Vajdic – Founder and Chief Executive Officer Jon Hunt – Chief Business Officer Rick Brounstein – Chief Financial Officer Conference Call Participants Jason Kolbert – Dawson James Bill Sutherland – The Benchmark Company Operator Greetings, and welcome to the HeartBeam Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A questio ...

Heart Attack Detection ■ wood Third Quarter 2022 Financial Results Conference Call NASDAQ: BEAT November 10, 2022 Third Quarter 2022 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives of management for futu ...

Table of contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BEAT NASDAQ Warrants BEATW NASDAQ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____ ...